CAScination AG has signed a distribution agreement with French company Mepy Système. “In the last 30 years they have built up an incredibly positive track record in the medical devices industry. We are very pleased to start the collaboration with Mepy Système. Together we will bring CAScination’s solutions for tumor treatment to patients in France”, says Frank Koall, Chief Commerial Officer at CAScination AG.
Mepy Système CEO Vincent Papelier shares the same enthusiasm about the mutual partnership and the prospects of introducing CAS-One to the French market: “When we saw the CAS-One live during an ablation procedure, we were impressed by the precision, the speed and the easy workflow. Then later when we learned about the clinical evidence supporting of faster procedure times and higher survival rates for patients using the CAS-One IR, we really wanted to get involved in distributing CAScination’s solution for percutaneous tumor treatment.”
With the swift workflow of CAS-One and the possibility to successfully perform interventions even in difficult locations in mind, Mepy Système sees a great potential for the use of CAS-One in France. “CAS-One is interesting for centers where the ablation volume is high and where difficult procedures are performed on a regular basis. CAScination will help making the procedures safer. At the same timetime, it facilitates lowering the recurrence rates”, Vincent Papelier is convinced.
Since 1989 Mepy Système has been specialized in the distribution of medical equipment. The Toulouse based company firmly focuses on high technicality to enable hospitals and clinics to take advantage of the best medical technology to provide diagnostic accuracy, patient comfort, practitioner comfort and speed of execution. Mepy Système is one of the leading distributors of medical imaging solutions in France with many healthcare institutions among their customers.
CAS-One is a navigation system for percutaneous interventions that is based on a highly standardized workflow and allows the interventionist to achieve a high degree of precision and quality in treatments. The system is currently in use in over 30 hospitals in Europe and Asia. In Switzerland most ablation centers use navigation technology by CAScination to offer better treatment to patients suffering from liver, renal or lung cancer. Since its introduction to the market in 2013 a total number of almost 3.000 procedures have been performed with CAS-One worldwide.
CAScination AG is an award-winning medical technology company dedicated to development, manufacturing and commercialization of innovations in computer-assisted and image-guided surgery. Our trailblazing navigation systems and surgical robots are designed to improve outcomes for patients undergoing surgical or interventional procedures and offer new perspectives to patients worldwide. Our CAS-One planning and navigation system is used to treat patients suffering from soft tissue cancer (e.g., liver cancer) by many hospitals across Europe, and we are developing further applications in a number of disease areas.
Fon + 41 (0) 31 552 0440